Gedeon Richter Chief Makes Biosimilars Prophecy
As Company Discuss Sales Prospects For Coming Quarters
Executive Summary
Gedeon Richter has high ambitions for biosimilars, recently penning a deal to bring in a tocilizumab biosimilar that is currently under development. During its first-quarter earnings call, the Hungarian company’s CEO gave his current thinking on how payers may treat biosimilars amidst the COVID-19 pandemic.
You may also be interested in...
Amgen Launches Rituxan Rival In US
Amgen has announced the launch of its biosimilar version of Rituxan (rituximab), Riabni, in the US market, further expanding the firm’s oncology biosimilars portfolio.
Sandoz Foresees Biosimilars Unlocking Innovation
Sandoz’ global head of biopharmaceuticals says that in the context of COVID-19, biosimilars can play a key role to increase access and unlock savings that can be invested in innovation to support “the long-term sustainability of healthcare systems.”
Formycon Chief Sees COVID-19 Boosting Biosimilars
Formycon’s CEO has offered the latest indication that the coronavirus outbreak could provide a tailwind for biosimilars, as the firm gave an update on its biosimilars pipeline – including ranibizumab, ustekinumab, aflibercept and an undisclosed molecule, as well as other unrevealed projects – and how it has been affected by the pandemic.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: